{
    "clinical_study": {
        "@rank": "35042", 
        "arm_group": [
            {
                "arm_group_label": "Entelon tab. 150mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Celebrex cap.", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is planned to prove Entelon tab. arm is not inferior to Celebrex cap.\n      arm in terms of the efficacy and safety through the change of K-WOMAC's total score sum in\n      patients with osteoarthritis of knee."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety of Entelon Tab. 150mg in Patients With Osteoarthritis of Knee", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. both gender,35 years \u2264 age \u2264 75 years\n\n          2. patients with a diagnosis of OA(osteoarthritis) of the knee within 3 months prior to\n             study participation, as determined by the American College of Rheumatology clinical\n             and radiographic criteria as follows.\n\n               1. knee arthralgia\n\n               2. more than one case among\n\n                    -  50 years or over\n\n                         -  morning stiffness less than 30 min\n\n                              -  friction sound\n\n               3. osteophyte in radiography\n\n          3. Kellgren and Lawrence Scale Grade II~III\n\n          4. total sum of K-WOMAC Scale more than 30\n\n          5. negative results in pregnancy test of urine in screening period\n\n          6. if women in childbearing age, medically reliable contraception or menopause\n\n          7. patients who give written consent of agreement to voluntarily participate in the\n             clinical study\n\n          8. patients who can read and understand written instructions\n\n        Exclusion Criteria:\n\n          1. patients whose total sum of K-WOMAC in visit 2 is less than that in visit 1\n\n          2. fibromyalgic, anserine bursitis, infectious arthritis, rheumatoid arthritis,\n             ankylosing spondylitis, gout or pseudogout\n\n          3. knee OA with secondary causes including major dysplastic or congenital malformation,\n             ochronosis, acromegaly, Hemochromatosis, Wilson's disease or primary\n             osteochondromatosis\n\n          4. anatomical malformation, disease of vertebra or other lower extremities or other\n             disease of orthopedics which can disturb the evaluation of the target joint\n\n          5. wound, inflammation or avascular necrosis of the target joint or arthroscopy within 6\n             months prior to study participation\n\n          6. patients with administration of injectable hyaluronic acid to the target joint within\n             6 months prior to study participation\n\n          7. severe ischaemic heart diseases, peripheral artery disease and/or cerebrovascular\n             disease, congestive heart failure, active bronchial asthma\n\n          8. medical history of malignant tumor\n\n          9. active peptic ulcer, gastrointestinal tract bleeding or inflammatory bowel disease\n\n         10. hypersensitivity with  aspirin, celecoxib, corticosteroid, acetaminophen, sulfonamide\n             derivatives or vitis vinifera or intolerance with fructose, glucose or galactose\n\n         11. continuously(1 week or more) oral or intraarticular administration of corticosteroids\n             within 12 weeks prior to study participation\n\n         12. pregnant or lactating women\n\n         13. patients who have experience to participate in other clinical trial within 4 weeks\n             prior to study participation\n\n         14. ALT, AST and Serum Creatinine \u2265 2\u00d7UNL\n\n         15. drug administration after diagnosing as alcoholic or psychical disease\n\n         16. patients whom the investigators judge as improper to participate in this clinical\n             trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "336", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768520", 
            "org_study_id": "HL_ENTR_302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Entelon tab. 150mg", 
                "description": "morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex\nevening : 1 tab. of active Entelon 150mg", 
                "intervention_name": "Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celebrex cap.", 
                "description": "morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex\nevening : 1 tab. of placebo Entelon 150mg", 
                "intervention_name": "Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex\nevening : 1 tab. of placebo Entelon 150mg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2013", 
        "location": {
            "contact": {
                "email": "solan42@naver.com", 
                "last_name": "Ji Sun Park, CRC", 
                "phone": "82 32 340 7236"
            }, 
            "contact_backup": {
                "email": "cutty0314@hanlim.com", 
                "last_name": "Su Yon Kim, CRM", 
                "phone": "82 2 3489 6167"
            }, 
            "facility": {
                "address": {
                    "city": "Bucheon", 
                    "country": "Korea, Republic of", 
                    "state": "Kyoung-gi do", 
                    "zip": "420-717"
                }, 
                "name": "The Catholic University of Korea, Bucheon St. Mary's Hospital"
            }, 
            "investigator": {
                "last_name": "Jun Ki Min, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "For 12 Weeks, the Multi-center, Randomized, Double-blinded, Clinical Study to Evaluate the Efficacy and Safety of Entelon Tab. 150mg Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee (Phase III)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the change of total sum of K-WOMAC(Korean The Western Ontario and McMaster Universities Arthritis Index)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks from first drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "for the entire study period(12 weeks)"
        }, 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}